The United Kingdom’s innovation agency is providing funding to set up an antibiotic drug discovery unit.

A new deal answers Lilly's concerns that Ignyta wasn't holding up its end of the license disease for taladegib.

A phase 2 trial of Xenon Pharmaceuticals’ acne candidate XEN801 has missed its primary and key secondary efficacy endpoints.

During his budget blueprint announced earlier this month, President Donald Trump announced swingeing cutbacks across federal programs, with the National…

Former FDA chief Califf leads a PCORI-backed research foundation, ex-Shire exec Shepard jumped to Eisai's oncology business, and Forty Seven hired former…

Fierce 15 winner C4 Therapeutics has become the latest biopharma to strike a deal with the Google-backed life sciences company Calico, although true to its…

Shares in Ultragenyx weakened after a midpipeline drug candidate missed its targets in a trial for a rare genetic disorder.

In this week's EuroBiotech Report, AstraZeneca rejected by FDA, Novartis fails phase 3, Pulmocide raises $30 million and more.

In our EuroBiotech roundup this week, AB shares jump on phase 3 ALS data, Advicenne raises €16 million, Galapagos advances AbbVie-partnered drug and more.

Biotech